{"id":"https://openalex.org/W5952523","doi":"https://doi.org/10.1200/jco.2006.24.18_suppl.14522","title":"USP2a is an oncogenic isopeptidase and a potential target in prostate cancer","display_name":"USP2a is an oncogenic isopeptidase and a potential target in prostate cancer","publication_year":2006,"publication_date":"2006-06-20","ids":{"openalex":"https://openalex.org/W5952523","doi":"https://doi.org/10.1200/jco.2006.24.18_suppl.14522","mag":"5952523"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2006.24.18_suppl.14522","doi":"https://doi.org/10.1200/jco.2006.24.18_suppl.14522","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2006.24.18_suppl.14522","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5085778676","display_name":"Carmen Priolo","orcid":"https://orcid.org/0000-0001-5716-3642","observed_orcids":["https://orcid.org/0000-0001-5716-3642"]},"institutions":[{"id":"https://openalex.org/I1283582996","display_name":"Novartis (Switzerland)","ror":"https://ror.org/02f9zrr09","country_code":"CH","type":"company","lineage":["https://openalex.org/I1283582996"]},{"id":"https://openalex.org/I170897317","display_name":"Duke University","ror":"https://ror.org/00py81415","country_code":"US","type":"education","lineage":["https://openalex.org/I170897317"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]},{"id":"https://openalex.org/I4210155236","display_name":"National Research Council","ror":"https://ror.org/04zaypm56","country_code":"IT","type":"nonprofit","lineage":["https://openalex.org/I4210155236"]}],"countries":["CH","IT","US"],"is_corresponding":false,"raw_author_name":"C. Priolo","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA; INeMM, Consiglio Nazionale delle Ricerche, Rome, Italy; Duke Institute for Genome Science and Policy, Durham, NC; Novartis Pharmaceuticals, Basel, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA; INeMM, Consiglio Nazionale delle Ricerche, Rome, Italy; Duke Institute for Genome Science and Policy, Durham, NC; Novartis Pharmaceuticals, Basel, Switzerland","institution_ids":["https://openalex.org/I1283582996","https://openalex.org/I170897317","https://openalex.org/I4210117453","https://openalex.org/I4210155236"]}]},{"author_position":"middle","author":{"id":null,"display_name":"D. Tang","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1283582996","display_name":"Novartis (Switzerland)","ror":"https://ror.org/02f9zrr09","country_code":"CH","type":"company","lineage":["https://openalex.org/I1283582996"]},{"id":"https://openalex.org/I170897317","display_name":"Duke University","ror":"https://ror.org/00py81415","country_code":"US","type":"education","lineage":["https://openalex.org/I170897317"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]},{"id":"https://openalex.org/I4210155236","display_name":"National Research Council","ror":"https://ror.org/04zaypm56","country_code":"IT","type":"nonprofit","lineage":["https://openalex.org/I4210155236"]}],"countries":["CH","IT","US"],"is_corresponding":false,"raw_author_name":"D. Tang","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA; INeMM, Consiglio Nazionale delle Ricerche, Rome, Italy; Duke Institute for Genome Science and Policy, Durham, NC; Novartis Pharmaceuticals, Basel, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA; INeMM, Consiglio Nazionale delle Ricerche, Rome, Italy; Duke Institute for Genome Science and Policy, Durham, NC; Novartis Pharmaceuticals, Basel, Switzerland","institution_ids":["https://openalex.org/I1283582996","https://openalex.org/I170897317","https://openalex.org/I4210117453","https://openalex.org/I4210155236"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5046386191","display_name":"Mohan Brahmandam","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1283582996","display_name":"Novartis (Switzerland)","ror":"https://ror.org/02f9zrr09","country_code":"CH","type":"company","lineage":["https://openalex.org/I1283582996"]},{"id":"https://openalex.org/I170897317","display_name":"Duke University","ror":"https://ror.org/00py81415","country_code":"US","type":"education","lineage":["https://openalex.org/I170897317"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]},{"id":"https://openalex.org/I4210155236","display_name":"National Research Council","ror":"https://ror.org/04zaypm56","country_code":"IT","type":"nonprofit","lineage":["https://openalex.org/I4210155236"]}],"countries":["CH","IT","US"],"is_corresponding":false,"raw_author_name":"M. Brahmandam","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA; INeMM, Consiglio Nazionale delle Ricerche, Rome, Italy; Duke Institute for Genome Science and Policy, Durham, NC; Novartis Pharmaceuticals, Basel, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA; INeMM, Consiglio Nazionale delle Ricerche, Rome, Italy; Duke Institute for Genome Science and Policy, Durham, NC; Novartis Pharmaceuticals, Basel, Switzerland","institution_ids":["https://openalex.org/I1283582996","https://openalex.org/I170897317","https://openalex.org/I4210117453","https://openalex.org/I4210155236"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5083054290","display_name":"Barbara Benassi","orcid":"https://orcid.org/0000-0002-6570-4434","observed_orcids":["https://orcid.org/0000-0002-6570-4434"]},"institutions":[{"id":"https://openalex.org/I1283582996","display_name":"Novartis (Switzerland)","ror":"https://ror.org/02f9zrr09","country_code":"CH","type":"company","lineage":["https://openalex.org/I1283582996"]},{"id":"https://openalex.org/I170897317","display_name":"Duke University","ror":"https://ror.org/00py81415","country_code":"US","type":"education","lineage":["https://openalex.org/I170897317"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]},{"id":"https://openalex.org/I4210155236","display_name":"National Research Council","ror":"https://ror.org/04zaypm56","country_code":"IT","type":"nonprofit","lineage":["https://openalex.org/I4210155236"]}],"countries":["CH","IT","US"],"is_corresponding":false,"raw_author_name":"B. Benassi","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA; INeMM, Consiglio Nazionale delle Ricerche, Rome, Italy; Duke Institute for Genome Science and Policy, Durham, NC; Novartis Pharmaceuticals, Basel, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA; INeMM, Consiglio Nazionale delle Ricerche, Rome, Italy; Duke Institute for Genome Science and Policy, Durham, NC; Novartis Pharmaceuticals, Basel, Switzerland","institution_ids":["https://openalex.org/I1283582996","https://openalex.org/I170897317","https://openalex.org/I4210117453","https://openalex.org/I4210155236"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5045074422","display_name":"Ewa Sici\u0144ska","orcid":"https://orcid.org/0000-0001-7187-319X","observed_orcids":["https://orcid.org/0000-0001-7187-319X"]},"institutions":[{"id":"https://openalex.org/I1283582996","display_name":"Novartis (Switzerland)","ror":"https://ror.org/02f9zrr09","country_code":"CH","type":"company","lineage":["https://openalex.org/I1283582996"]},{"id":"https://openalex.org/I170897317","display_name":"Duke University","ror":"https://ror.org/00py81415","country_code":"US","type":"education","lineage":["https://openalex.org/I170897317"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]},{"id":"https://openalex.org/I4210155236","display_name":"National Research Council","ror":"https://ror.org/04zaypm56","country_code":"IT","type":"nonprofit","lineage":["https://openalex.org/I4210155236"]}],"countries":["CH","IT","US"],"is_corresponding":false,"raw_author_name":"E. Sicinska","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA; INeMM, Consiglio Nazionale delle Ricerche, Rome, Italy; Duke Institute for Genome Science and Policy, Durham, NC; Novartis Pharmaceuticals, Basel, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA; INeMM, Consiglio Nazionale delle Ricerche, Rome, Italy; Duke Institute for Genome Science and Policy, Durham, NC; Novartis Pharmaceuticals, Basel, Switzerland","institution_ids":["https://openalex.org/I1283582996","https://openalex.org/I170897317","https://openalex.org/I4210117453","https://openalex.org/I4210155236"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5076818447","display_name":"Shuji Ogino","orcid":"https://orcid.org/0000-0002-3909-2323","observed_orcids":["https://orcid.org/0000-0002-3909-2323"]},"institutions":[{"id":"https://openalex.org/I1283582996","display_name":"Novartis (Switzerland)","ror":"https://ror.org/02f9zrr09","country_code":"CH","type":"company","lineage":["https://openalex.org/I1283582996"]},{"id":"https://openalex.org/I170897317","display_name":"Duke University","ror":"https://ror.org/00py81415","country_code":"US","type":"education","lineage":["https://openalex.org/I170897317"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]},{"id":"https://openalex.org/I4210155236","display_name":"National Research Council","ror":"https://ror.org/04zaypm56","country_code":"IT","type":"nonprofit","lineage":["https://openalex.org/I4210155236"]}],"countries":["CH","IT","US"],"is_corresponding":false,"raw_author_name":"S. Ogino","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA; INeMM, Consiglio Nazionale delle Ricerche, Rome, Italy; Duke Institute for Genome Science and Policy, Durham, NC; Novartis Pharmaceuticals, Basel, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA; INeMM, Consiglio Nazionale delle Ricerche, Rome, Italy; Duke Institute for Genome Science and Policy, Durham, NC; Novartis Pharmaceuticals, Basel, Switzerland","institution_ids":["https://openalex.org/I1283582996","https://openalex.org/I170897317","https://openalex.org/I4210117453","https://openalex.org/I4210155236"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5001489017","display_name":"Antonella Farsetti","orcid":"https://orcid.org/0000-0002-8603-7925","observed_orcids":["https://orcid.org/0000-0002-8603-7925"]},"institutions":[{"id":"https://openalex.org/I1283582996","display_name":"Novartis (Switzerland)","ror":"https://ror.org/02f9zrr09","country_code":"CH","type":"company","lineage":["https://openalex.org/I1283582996"]},{"id":"https://openalex.org/I170897317","display_name":"Duke University","ror":"https://ror.org/00py81415","country_code":"US","type":"education","lineage":["https://openalex.org/I170897317"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]},{"id":"https://openalex.org/I4210155236","display_name":"National Research Council","ror":"https://ror.org/04zaypm56","country_code":"IT","type":"nonprofit","lineage":["https://openalex.org/I4210155236"]}],"countries":["CH","IT","US"],"is_corresponding":false,"raw_author_name":"A. Farsetti","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA; INeMM, Consiglio Nazionale delle Ricerche, Rome, Italy; Duke Institute for Genome Science and Policy, Durham, NC; Novartis Pharmaceuticals, Basel, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA; INeMM, Consiglio Nazionale delle Ricerche, Rome, Italy; Duke Institute for Genome Science and Policy, Durham, NC; Novartis Pharmaceuticals, Basel, Switzerland","institution_ids":["https://openalex.org/I1283582996","https://openalex.org/I170897317","https://openalex.org/I4210117453","https://openalex.org/I4210155236"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5038843491","display_name":"Alessandro Porrello","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1283582996","display_name":"Novartis (Switzerland)","ror":"https://ror.org/02f9zrr09","country_code":"CH","type":"company","lineage":["https://openalex.org/I1283582996"]},{"id":"https://openalex.org/I170897317","display_name":"Duke University","ror":"https://ror.org/00py81415","country_code":"US","type":"education","lineage":["https://openalex.org/I170897317"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]},{"id":"https://openalex.org/I4210155236","display_name":"National Research Council","ror":"https://ror.org/04zaypm56","country_code":"IT","type":"nonprofit","lineage":["https://openalex.org/I4210155236"]}],"countries":["CH","IT","US"],"is_corresponding":false,"raw_author_name":"A. Porrello","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA; INeMM, Consiglio Nazionale delle Ricerche, Rome, Italy; Duke Institute for Genome Science and Policy, Durham, NC; Novartis Pharmaceuticals, Basel, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA; INeMM, Consiglio Nazionale delle Ricerche, Rome, Italy; Duke Institute for Genome Science and Policy, Durham, NC; Novartis Pharmaceuticals, Basel, Switzerland","institution_ids":["https://openalex.org/I1283582996","https://openalex.org/I170897317","https://openalex.org/I4210117453","https://openalex.org/I4210155236"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5058375967","display_name":"Phillip G. Febbo","orcid":"https://orcid.org/0000-0002-6496-4664","observed_orcids":["https://orcid.org/0000-0002-6496-4664"]},"institutions":[{"id":"https://openalex.org/I1283582996","display_name":"Novartis (Switzerland)","ror":"https://ror.org/02f9zrr09","country_code":"CH","type":"company","lineage":["https://openalex.org/I1283582996"]},{"id":"https://openalex.org/I170897317","display_name":"Duke University","ror":"https://ror.org/00py81415","country_code":"US","type":"education","lineage":["https://openalex.org/I170897317"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]},{"id":"https://openalex.org/I4210155236","display_name":"National Research Council","ror":"https://ror.org/04zaypm56","country_code":"IT","type":"nonprofit","lineage":["https://openalex.org/I4210155236"]}],"countries":["CH","IT","US"],"is_corresponding":false,"raw_author_name":"P. G. Febbo","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA; INeMM, Consiglio Nazionale delle Ricerche, Rome, Italy; Duke Institute for Genome Science and Policy, Durham, NC; Novartis Pharmaceuticals, Basel, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA; INeMM, Consiglio Nazionale delle Ricerche, Rome, Italy; Duke Institute for Genome Science and Policy, Durham, NC; Novartis Pharmaceuticals, Basel, Switzerland","institution_ids":["https://openalex.org/I1283582996","https://openalex.org/I170897317","https://openalex.org/I4210117453","https://openalex.org/I4210155236"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5046240192","display_name":"Johann Zimmermann","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1283582996","display_name":"Novartis (Switzerland)","ror":"https://ror.org/02f9zrr09","country_code":"CH","type":"company","lineage":["https://openalex.org/I1283582996"]},{"id":"https://openalex.org/I170897317","display_name":"Duke University","ror":"https://ror.org/00py81415","country_code":"US","type":"education","lineage":["https://openalex.org/I170897317"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]},{"id":"https://openalex.org/I4210155236","display_name":"National Research Council","ror":"https://ror.org/04zaypm56","country_code":"IT","type":"nonprofit","lineage":["https://openalex.org/I4210155236"]}],"countries":["CH","IT","US"],"is_corresponding":false,"raw_author_name":"J. Zimmermann","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA; INeMM, Consiglio Nazionale delle Ricerche, Rome, Italy; Duke Institute for Genome Science and Policy, Durham, NC; Novartis Pharmaceuticals, Basel, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA; INeMM, Consiglio Nazionale delle Ricerche, Rome, Italy; Duke Institute for Genome Science and Policy, Durham, NC; Novartis Pharmaceuticals, Basel, Switzerland","institution_ids":["https://openalex.org/I1283582996","https://openalex.org/I170897317","https://openalex.org/I4210117453","https://openalex.org/I4210155236"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5071763026","display_name":"Massimo F. Loda","orcid":"https://orcid.org/0000-0001-9674-8379","observed_orcids":["https://orcid.org/0000-0001-9674-8379"]},"institutions":[{"id":"https://openalex.org/I1283582996","display_name":"Novartis (Switzerland)","ror":"https://ror.org/02f9zrr09","country_code":"CH","type":"company","lineage":["https://openalex.org/I1283582996"]},{"id":"https://openalex.org/I170897317","display_name":"Duke University","ror":"https://ror.org/00py81415","country_code":"US","type":"education","lineage":["https://openalex.org/I170897317"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]},{"id":"https://openalex.org/I4210155236","display_name":"National Research Council","ror":"https://ror.org/04zaypm56","country_code":"IT","type":"nonprofit","lineage":["https://openalex.org/I4210155236"]}],"countries":["CH","IT","US"],"is_corresponding":false,"raw_author_name":"M. F. Loda","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA; INeMM, Consiglio Nazionale delle Ricerche, Rome, Italy; Duke Institute for Genome Science and Policy, Durham, NC; Novartis Pharmaceuticals, Basel, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA; INeMM, Consiglio Nazionale delle Ricerche, Rome, Italy; Duke Institute for Genome Science and Policy, Durham, NC; Novartis Pharmaceuticals, Basel, Switzerland","institution_ids":["https://openalex.org/I1283582996","https://openalex.org/I170897317","https://openalex.org/I4210117453","https://openalex.org/I4210155236"]}]}],"institutions":[],"countries_distinct_count":3,"institutions_distinct_count":4,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"24","issue":"18_suppl","first_page":"14522","last_page":"14522"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11041","display_name":"Ubiquitin and proteasome pathways","score":0.9843999743461609,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T11041","display_name":"Ubiquitin and proteasome pathways","score":0.9843999743461609,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10543","display_name":"Prostate Cancer Treatment and Research","score":0.013299999758601189,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12465","display_name":"Cancer, Lipids, and Metabolism","score":0.00039999998989515007,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/isopeptidase","display_name":"isopeptidase","score":0.8690000176429749},{"id":"https://openalex.org/keywords/deubiquitinase","display_name":"deubiquitinase","score":0.9150000214576721},{"id":"https://openalex.org/keywords/prostate-cancer","display_name":"prostate cancer","score":0.9769999980926514},{"id":"https://openalex.org/keywords/oncogenes","display_name":"oncogenes","score":0.7979999780654907},{"id":"https://openalex.org/keywords/fatty-acid-synthase","display_name":"fatty acid synthase","score":0.9100000262260437},{"id":"https://openalex.org/keywords/protein-stabilization","display_name":"protein stabilization","score":0.6340000033378601},{"id":"https://openalex.org/keywords/apoptosis-resistance","display_name":"apoptosis resistance","score":0.6970000267028809},{"id":"https://openalex.org/keywords/cisplatin-resistance","display_name":"cisplatin resistance","score":0.75},{"id":"https://openalex.org/keywords/paclitaxel-resistance","display_name":"paclitaxel resistance","score":0.9589999914169312},{"id":"https://openalex.org/keywords/androgen-regulation","display_name":"androgen regulation","score":0.6340000033378601},{"id":"https://openalex.org/keywords/therapeutic-target","display_name":"therapeutic target","score":0.6159999966621399},{"id":"https://openalex.org/keywords/gene-expression-profiling","display_name":"gene expression profiling","score":0.6840000152587891},{"id":"https://openalex.org/keywords/tumor-cell-proliferation","display_name":"tumor cell proliferation","score":0.4869999885559082},{"id":"https://openalex.org/keywords/tumor-xenografts","display_name":"tumor xenografts","score":0.5379999876022339},{"id":"https://openalex.org/keywords/lipid-metabolism","display_name":"lipid metabolism","score":0.47600001096725464},{"id":"https://openalex.org/keywords/tumor-suppressor-genes","display_name":"tumor suppressor","score":0.46700000762939453}],"concepts":[{"id":"https://openalex.org/C2776438761","wikidata":"https://www.wikidata.org/wiki/Q5206280","display_name":"DU145","level":5,"score":0.9354655146598816},{"id":"https://openalex.org/C2779723316","wikidata":"https://www.wikidata.org/wiki/Q6459234","display_name":"LNCaP","level":4,"score":0.8649507761001587},{"id":"https://openalex.org/C190283241","wikidata":"https://www.wikidata.org/wiki/Q14599311","display_name":"Apoptosis","level":2,"score":0.6673479676246643},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.5862038731575012},{"id":"https://openalex.org/C54009773","wikidata":"https://www.wikidata.org/wiki/Q1429031","display_name":"Transfection","level":3,"score":0.5298939347267151},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.5051682591438293},{"id":"https://openalex.org/C2780192828","wikidata":"https://www.wikidata.org/wiki/Q181257","display_name":"Prostate cancer","level":3,"score":0.4984867572784424},{"id":"https://openalex.org/C119056186","wikidata":"https://www.wikidata.org/wiki/Q1431332","display_name":"Gene silencing","level":3,"score":0.4978792667388916},{"id":"https://openalex.org/C207001950","wikidata":"https://www.wikidata.org/wiki/Q141124","display_name":"In vivo","level":2,"score":0.47225847840309143},{"id":"https://openalex.org/C81885089","wikidata":"https://www.wikidata.org/wiki/Q189082","display_name":"Cell culture","level":2,"score":0.4233022630214691},{"id":"https://openalex.org/C555283112","wikidata":"https://www.wikidata.org/wiki/Q1637543","display_name":"Carcinogenesis","level":3,"score":0.4152681827545166},{"id":"https://openalex.org/C153911025","wikidata":"https://www.wikidata.org/wiki/Q7202","display_name":"Molecular biology","level":1,"score":0.39642295241355896},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.3036670684814453},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.08826905488967896},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.0787750780582428},{"id":"https://openalex.org/C54355233","wikidata":"https://www.wikidata.org/wiki/Q7162","display_name":"Genetics","level":1,"score":0.0},{"id":"https://openalex.org/C150903083","wikidata":"https://www.wikidata.org/wiki/Q7108","display_name":"Biotechnology","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2006.24.18_suppl.14522","doi":"https://doi.org/10.1200/jco.2006.24.18_suppl.14522","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2006.24.18_suppl.14522","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.9391000270843506}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W1999816037","https://openalex.org/W2170417672","https://openalex.org/W7163199932","https://openalex.org/W4200554703","https://openalex.org/W2564979873","https://openalex.org/W2107857423","https://openalex.org/W7148917010","https://openalex.org/W2104424545","https://openalex.org/W4321093554","https://openalex.org/W6982652232"],"abstract_inverted_index":{"14522":[0],"Background:":[1],"De-ubiquitinating":[2],"enzymes":[3],"(isopeptidases)":[4],"remove":[5],"ubiquitin":[6],"side":[7],"chains":[8],"prior":[9],"to":[10,154,206,218,227,263],"degradation":[11],"by":[12,84,112,184,209,266],"the":[13,36,242,272],"proteosome":[14],"thus":[15],"stabilizing":[16],"their":[17],"protein":[18],"targets.":[19],"We":[20,53],"have":[21],"identified":[22],"a":[23,43,144,179,311],"novel":[24],"androgen":[25],"regulated":[26],"isopeptidase,":[27],"USP2a,":[28],"and":[29,34,62,66,81,98,102,125,149,174,187,211,293,296],"demonstrated":[30],"that":[31,203,285,307],"it":[32],"binds":[33],"prolongs":[35],"half-life":[37],"of":[38,49,115,151,170,192,241,252,271],"fatty":[39],"acid":[40],"synthase":[41],"(FAS),":[42],"key":[44],"enzyme":[45],"in":[46,60,63,72,96,108,118,130,139,143,147,157,161,172,178,195,232,250,278,291,294,299,315],"lipid":[47],"metabolism":[48],"tumor":[50],"cells.":[51,91,159],"Methods:":[52],"determined":[54],"whether":[55],"USP2a":[56,69,122,137,171,214,246,286],"has":[57],"oncogenic":[58],"properties":[59],"vitro":[61,292],"vivo.":[64],"Wild-type":[65,136],"catalytically":[67],"inactive":[68],"were":[70,87,94,128],"introduced":[71],"immortalized":[73],"normal":[74,97,264],"prostate":[75,104,133,254,301,316],"epithelial":[76],"cells":[77,117,141,176],"(AR-iPrECs).":[78],"Clonogenicity":[79],"assays":[80],"apoptosis":[82,196,207],"induction":[83,261],"chemotherapeutic":[85],"agents":[86],"performed":[88],"on":[89,200],"these":[90],"Anti-USP2a":[92],"siRNA":[93],"transfected":[95],"transformed":[99],"(LNCaP,":[100],"DU145":[101,175],"PC-3)":[103],"cell":[105],"lines.":[106],"Oncogenicity":[107],"vivo":[109,295],"was":[110,164,198,216,248],"shown":[111],"s.c.":[113],"injection":[114],"NIH3T3-USP2a":[116],"nude":[119,234],"mice.":[120],"Furthermore,":[121],"mRNA":[123,247],"expression":[124,269],"gene":[126],"microarrays":[127],"tested":[129],"52":[131],"human":[132,253],"adenocarcinomas.":[134],"Results:":[135],"overexpression":[138,215],"AR-iPrEC":[140],"resulted":[142,177],"significant":[145],"increase":[146],"number":[148],"size":[150],"colonies":[152],"compared":[153],"those":[155],"obtained":[156],"parental":[158],"Growth":[160],"soft":[162],"agar":[163],"significantly":[165],"enhanced":[166],"as":[167,288],"well.":[168],"Silencing":[169],"LNCAP":[173],"strong":[180],"apoptotic":[181],"effect,":[182],"evaluated":[183],"FACS":[185],"analysis":[186],"cleaved-PARP":[188],"expression.":[189],"The":[190],"role":[191],"this":[193,308],"isopeptidase":[194,309],"regulation":[197],"confirmed":[199],"AR-iPrEC-USP2a":[201],"cells,":[202,221],"showed":[204],"resistance":[205],"induced":[208],"cisplatin":[210],"taxol.":[212],"Importantly,":[213],"able":[217],"transform":[219],"NIH3T3":[220],"generating":[222],"greater":[223],"than":[224],"or":[225],"equal":[226],"0.5":[228],"cm":[229],"subcutaneous":[230],"tumors":[231,274],"12/12":[233],"mice":[235],"within":[236],"3":[237],"weeks,":[238],"while":[239],"none":[240],"negative":[243],"controls":[244],"grew.":[245],"overexpressed":[249,298],"39%":[251],"cancers,":[255],"showing":[256],"1.6\u2013104":[257],"(median":[258],"5.48)":[259],"fold":[260],"relative":[262],"tissues":[265],"qRT-PCR.":[267],"Gene":[268],"profiling":[270],"same":[273],"revealed":[275],"specific":[276],"signatures":[277],"USP2a-overexpressing":[279],"tumors.":[280],"Conclusions:":[281],"Our":[282],"results":[283],"demonstrate":[284],"behaves":[287],"an":[289],"oncogene":[290],"is":[297,310],"organ-confined":[300],"cancer.":[302,317],"These":[303],"data":[304],"strongly":[305],"suggest":[306],"potential":[312],"drug":[313],"target":[314],"[Table:":[318],"see":[319],"text]":[320]},"counts_by_year":[],"updated_date":"2026-09-29T14:09:16.559479","created_date":"2016-06-24T00:00:00"}